Drug Trial Radar · NCT03992404
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
603
Actual
Start
Sep 16, 2019
Primary completion
Jun 19, 2025
Study completion Apr 2027
Sponsor
- Lead sponsor
- Merz Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. The following 4 to 5 treatment cycles will investigate the safety and tolerability of treatment with NT 201 (botulinum toxin) when administered in doses between 400 and 800 Units (Open Label Extension Period). All participants will receive the treatment and the dose will depend on whether only lower limb spasticity or combined upper and lower limb spasticity are treated.
Conditions
- Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201Drug
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
PlaceboDrug
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at weeks 4 to 6Time frame: Baseline to week 4-6
- Co-Primary: Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6Time frame: Week 4-6
- Occurrence of treatment emergent adverse events [TEAEs] in the Main PeriodTime frame: Baseline to week 12
Locations
71 sites in 15 countries. Site status is shown where the registry gives one.
Physical Medicine and Rehabilitation at University of Alabama at Birmingham; Merz investigational site #0010479
Birmingham, Alabama
University of Arkansas for Medical Sciences, Merz investigational site #0010481
Little Rock, Arkansas
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center; Merz investigational site #0010184
Downey, California
New England institute for clinical research; Merz Investigational Site #0010441
Stamford, Connecticut
Nova Clinical Research, Merz investigational site #0010474
Brandenton, Florida
Brooks Rehabilitation Clinical Integration and Research, Merz investigational site #0010483
Jacksonville, Florida
Sarasota Memorial Health Care System, Rehabilitation Medicine, Merz investigational site #0010478
Sarasota, Florida
Neurology Center of New England P.C., Merz investigative site #0010476
Foxborough, Massachusetts
Howard A. Rusk Rehabilitation Center; Merz investigational site #0010283
Columbia, Missouri
Icahn School of Medicine at Mount Sinai, Neurology Department, Merz Investigational Site #0010191
New York, New York
Weill Cornell Medical Center, Department of Rehabilitation Medicine; Merz Investigational Site #0010440
New York, New York
University of Pittsburgh Medical Center, Physical Medicine & Rehabiliation, Merz Investigational Site #0010211
Pittsburgh, Pennsylvania
UT Southwestern Medical Center, Department of Physical Medicine & Rehabilitation, Merz investigational site #0010082
Dallas, Texas
University of Texas Health Science Center McGovern, Medical School Department of PM&R; merz investigational site #0010183
Houston, Texas
Medical College of Wisconsin,Department of PM&R, Merz Investigational Site #0010237
Milwaukee, Wisconsin
CHU Brugmann Neurology; Merz investigational site #0320015
Brussels, Belgium
UCL Bruxelles, Physical Medicine & Rehabilitation Department, Merz Investigational Site #0320013
Brussels, Belgium
UZ Leuven Pellenberg campus; Merz investigational site #0320014
Pellenberg, Belgium
UCL Mont Godinne, Physical Medicine & Rehabilitation Department; Merz Investigational Site #0320008
Yvoir, Belgium
Glenrose Rehabilitation Hospital, Merz investigational site #0010195
Edmonton, Canada
Neurology and Physiotherapy Skopalikova, Merz Investigational Site #4200049
Brno, Czechia
University Hospital Ostrava; Neurology Departement, Merz investigational site #4200024
Ostrava, Czechia
Pardubice Regional Hospital; Merz investigational site #4200025
Pardubice, Czechia
Raymond Poincaré University Hospital, Service de MPR Pôle Handicap-Rééducation, Merz Investigational site #00330018
Garches, France
CHU Lille/Hôpital Swynghedauw; investigational site # 0330045
Lille, France
Pôle Saint-Hélier; Merz investigational site #0330024
Rennes, France
Institut Universitaire de Readaptation Clemenceau, Physical Medicine / Rehabilitation Medecine, Merz Investigational site # 0330063
Strasbourg, France
Rangueil Hospital-University Hospital Center (CHU) of Toulouse, Médecine physique et de réadaptation, Merz investigational site #0330025
Toulouse, France
Uniklinik RWTH Aachen, Neurologie, Merz Investigational Site #0490191
Aachen, Germany
Neurologie Bewegt; Merz Investigational site #0490378
Berlin, Germany
University of Bonn Medical Center, Department of Neurodegenerative disease, Merz investigational site #0490390
Bonn, Germany
Heinrich Heine University Duesseldorf, Department of Neurology; Merz Investigational Site #0490071
Düsseldorf, Germany
Universitätsklinikum Hamburg-Eppendorf, Merz Investigational site #0490079
Hamburg, Germany
DKD HELIOS Medical Center, Fachbereich Neurologie, Merz Investigational Site #0490081
Wiesbaden, Germany
Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg, Merz Investigational Site #0490302
Würzburg, Germany
Petz Hospital, Neurology, Merz Investigational Site #0360010
Győr, Hungary
St.Damjan Hospital, Kisvarda; Merz investigational site #0360019
Kisvárda, Hungary
University of Szeged, Department of Neurology, Merz investigational site #0360008
Szeged, Hungary
Azienda Ospedaliera Universitaria Ospedali Riuniti Di Foggia; Merz Investigational Site #0390018
Foggia, Italy
IRCCS Ospedale Policlinico S. Martino, U.O.Complessa Riabilitazione e Rieducazione Funzionale; Merz investigational site #0390020
Genova, Italy
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.